Vaccine third dose 'likely' needed within 12 months, says Pfizer CEO

Lula Sharp
April 16, 2021

Pfizer announced earlier this month the results of its Phase 3 study of the company's COVID vaccine, suggesting a 91.3% effective rate against COVID-19 and 95.3% effective rate against severe COVID-19 for up to six months after the second dose.

According to The Hill, Pfizer and BioNTech said earlier this year they were testing the third dose of their vaccine against the COVID-19 variants that have spread worldwide.

Based on the data, the CEO said there was a need for re-vaccination between six and 12 months and also an annual re-vaccination.

The government has ordered 40 million doses of the Valneva jab for 2022, "should we need to revaccinate any of the United Kingdom population", its vaccine task force said earlier this year.

Health officials have previously raised the possibility that the public may need booster COVID-19 shots.

And Bulgarian Prime Minister Boyko Borissov warned earlier this week that Brussels was facing a huge price hike as it negotiates almost two billion additional doses of the vaccine for the coming years.

Bourla said during the event that COVID-19 variants would "play a key role" in determining what vaccinations will be needed in the future.

Flores killed SLO County coed while sexual assaulting her, DA alleges
Ruben Flore is arrested for accessory after the fact by the San Luis Obispo Sheriff's Department in the murder of Kristin Smart . Ruben Flores is charged with accessory after the fact since he helped hide the body of Smart after the murder, Dow said .


The announcement from Bourla comes on the heels of Moderna stating that the company hopes to have its booster ready by the fall to avoid a winter surge similar to what happened during the holiday season.

David Kessler, the head of US President Joe Biden's Covid-19 response team, warned a congressional committee on Thursday that Americans should expect to receive booster shots to defend against coronavirus variants.

He explained: "We don't know everything at this moment".

"It seems strong but there is some waning of that and no doubt the variants challenge".

Of 77 million people vaccinated in the United States, there have been 5,800 such breakthrough infections, Ms Walensky said, including 396 people who required hospitalisation and 74 who died.

Though, the vaccines have not yet been tested in on pregnant women, Dr. Al Khenyab has said that evidence from non-clinical studies of the Pfizer and BioNTech vaccine has been reviewed by the World Health Organization and the regulatory bodies in the USA, Canada and Europe and has raised no concerns about safety in pregnancy.

"So I think for planning purposes, planning purposes only, I think we should expect that we may have to boost".

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER